



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

European Society for Medical Oncology

IMMUNO-ONCOLOGY
SYMPOSIUM

**ESMO Symposium
on Immuno-Oncology
Programme book**

**Advances in cancer
immunotherapy; From
vaccines to antibodies
and cell therapies**

Geneva
Switzerland

15-16 NOVEMBER 2013

esmo.org

SYMPOSIUM PROGRAMME

Friday, 15 November 2013

10:00	Welcome coffee
10:30/	Welcome
10:45	<i>George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland</i>
10:45/	The role of the immune system in cancer
11:45	<i>Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland</i>
10:45	Engineering T cells to overcome tolerance <i>Carl H. June, Philadelphia, PA, US</i>
11:15	Checkpoint blockade <i>Ignacio Melero, Pamplona, Spain</i>
11:45/	Immuno-Oncology clinical studies across tumour types I
13:15	<i>Chair: Martin Gore, London, UK</i>
11:45	Melanoma as proof of concept <i>Olivier Michielin, Lausanne, Switzerland</i>
12:10	Prostate cancer <i>Winald Gerritsen, Amsterdam, Netherlands</i>
12:35	Renal cancer <i>Martin Gore, London, UK</i>
13:00	General discussion / Q&A
13:15	Lunch
14:15/	Immuno-Oncology clinical studies across tumour types II
16:00	<i>Chair: George Coukos, Lausanne, Switzerland</i>
14:15	Lung cancer: Vaccination approaches <i>Johan Vansteenkiste, Leuven, Belgium</i>
14:35	Lung cancer: Other <i>Scott J. Antonia, Tampa, FL, US</i>
14:55	Ovarian cancer <i>George Coukos, Lausanne, Switzerland</i>
15:20	Brain tumours <i>Pierre-Yves Dietrich, Geneva, Switzerland</i>
15:45	General discussion / Q&A
16:00	Coffee break

-
- 16:30/ **Immune checkpoint inhibitors**
17:05 *Chair: Solange Peters, Lausanne, Switzerland*
- 16:30 Two cases of immunotherapy with monoclonal antibodies
Ignacio Melero, Pamplona, Spain
- 16:45 Case report of a serious adverse event upon administration of T cells transduced with a MART-1 specific T cell receptor
Joost van den Berg, Amsterdam, Netherlands
- 16:55 General discussion / Q&A
-

- 17:05/ **Clinical experience and management of risk:benefit**
17:50 *Chair: Olivier Michielin, Lausanne, Switzerland*
- 17:05 Panel Discussion
Rolf A. Stahel, Zurich, Switzerland
George Coukos, Lausanne, Switzerland
Solange Peters, Lausanne, Switzerland
- 17:50 Cocktail
-

Saturday, 16 November 2013

- 08:30/ **Implications for clinical practice**
10:25 *Chair: Jedd D. Wolchok, New York, NY, US*
- 08:30 Response evaluation
Jedd D. Wolchok, New York, NY, US
- 08:55 Monitoring of immune response
Michael Kalos, Philadelphia, PA, US
- 09:20 Biomarkers, tissue analysis and potential applications
Jerome Galon, Paris, France
- 09:45 The model of breast cancer
Giuseppe Curigliano, Milan, Italy
- 10:10 General discussion / Q&A
-
- 10:25 Coffee break
-
- 10:45/ **Promising therapeutic strategies**
12:15 *Chair: Ton N. Schumacher, Amsterdam, Netherlands*
- 10:45 Novel approaches to molecular vaccines
Sebastian Kreiter, Mainz, Germany
- 11:10 Dissecting adoptive T cell therapies
Ton N. Schumacher, Amsterdam, Netherlands
- 11:35 Checkpoint inhibitors PD1, PDL1 vs CTLA-4
Caroline Robert, Villejuif, France
- 12:00 General Discussion/ Q&A
-
- 12:15 Lunch
-

13:15/ 15:15 Integration with other therapies / combination approaches

Chair: Cornelis J. Melief, Leiden, Netherlands

13:15 Surgery with focus on TILs
Laszlo G. Radvanyi, Houston, TX, US

13:40 Radiotherapy
Dirk De Ruyscher, Leuven, Belgium

14:05 Chemotherapy combinations
Martin Reck, Grosshansdorf, Germany

14:30 Immunotherapy combinations
Cornelis J. Melief, Leiden, Netherlands

14:55 General discussion/ Q&A

15:15/ Outlook and panel discussion

16:00 *Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland*

15:15 Current therapeutic options and development strategies
George Coukos, Lausanne, Switzerland

15:40 Panel discussion

16:00 Closing remarks

Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland

INVITED SPEAKER DISCLOSURES

Antonia Scott J.	The author has declared no conflicts of interest
Coukos George	The author has declared no conflicts of interest
Curigliano Giuseppe	The author has declared no conflicts of interest
De Ruyscher Dirk	The author has declared no conflicts of interest
Dietrich Pierre-Yves	Receipt of grants/research supports: Amgen, Sanofi, Roche, Novartis. Receipt of honoraria or consultation fees: BMS
Galon Jerome	No disclosure at time of going to press
Gerritsen Winald	Consultancy: Aglaia Biomedical Ventures. Honorarium: supervisory board PsytoBe. Speakers fee: J&J, BMS. Advisory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, Astellas, Bayer, Merck
June Carl H.	Sponsored research grant and royalties from Novartis
Kalos Michael	Receipt of honoraria or consultation fees: Novartis. Other supports: Royalties and Licensing of Cartiq Technology to Novartis
Melief Cornelis J.	Receipt of honoraria or consultation fees: CSO (employed in CSO). Stock shareholder: in possession of Stock appreciation rights
Melero Ignacio	Receipt of grants / research supports: BMS. Receipt of honoraria or consultation fees: BMS, AstraZeneca, Merck Serono, Miltenyi
Michielin Olivier	The author has declared no conflicts of interest
Nathan Paul	Receipt of grants/research supports: BMS. Participation in a company sponsored speaker's bureau: BMS
Peters Solange	The author has declared no conflicts of interest
Radvanyi Laszlo G.	The author has declared no conflicts of interest
Reck Martin	No disclosure at time of going to press
Robert Caroline	Receipt of honoraria or consultation fees: BMS, Merck, Roche, Novartis, GSK
Sahin Ugur	The author has declared no conflicts of interest
Schumacher Ton N.	The author has declared no conflicts of interest
Stahel Rolf A.	Receipt of honoraria or consultation fees: Abbott, Amgen, Astellas, AZ, Genentech, Eli Lilly, Merck, Novartis, Roche
Vansteenkiste Johan	Receipt of grants/research supports: Astra-Zeneca Chair in Personalised Lung Cancer Care at the Leuven University (research funding). Receipt of honoraria or consultation fees: GSK-BIO, Merck-Serono
Wolchok Jedd D.	Receipt of grants/research supports: GSK, BMS. Receipt of honoraria or consultation fees: Ziopharm, BMS, GSK, J&J